National trends in the ambulatory treatment of hypertension in the United States, 1997-2012.

by Meijia Zhou, Matthew Daubresse, Randall S Stafford, G Caleb Alexander
Published 2015-01-01

Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study

by G Caleb Alexander, Thomas J Moore, James Heyward, Gerard Anderson
Published 2020-06-01

Promotion of prescription drugs to consumers and providers, 2001-2010.

by Rachel Kornfield, Julie Donohue, Ernst R Berndt, G Caleb Alexander
Published 2013-01-01

Branded prescription drug spending: a framework to evaluate policy options

by Jeromie Ballreich, G. Caleb Alexander, Mariana Socal, Taruja Karmarkar, Gerard Anderson
Published 2017-12-01

Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.

by Yunwen Xu, Scott J Pilla, G Caleb Alexander, Irene B Murimi
Published 2019-01-01

Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States

by James M. Stevenson, G. Caleb Alexander, Natasha Palamuttam, Hemalkumar B. Mehta
Published 2021-01-01

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.

by James Heyward, Omar Mansour, Lily Olson, Sonal Singh, G Caleb Alexander
Published 2020-01-01

Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study

by G Caleb Alexander, Thomas J Moore, Stefan P Kruszewski, Phillip W Wirtz
Published 2021-08-01

Medical use and combination drug therapy among US adult users of central nervous system stimulants: a cross-sectional analysis

by G Caleb Alexander, Thomas J Moore, Phillip W Wirtz, Jill N Curran
Published 2023-04-01

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

by G Caleb Alexander, Hemalkumar B Mehta, Thomas J Moore, Jodi B Segal
Published 2020-06-01

Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review

by Thomas Metkus, Jill Curran, Shanshan Lin, Dima M. Qato, G. Caleb Alexander
Published 2024-02-01

Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.

by Irene B Murimi-Worstell, Jeromie M Ballreich, Marissa J Seamans, G Caleb Alexander
Published 2019-01-01

Impact of Race on Classification of Atherosclerotic Risk Using a National Cardiovascular Risk Prediction Tool

by Jarett R. Beaudoin, MD, MPH, Jill Curran, MS, G. Caleb Alexander, MD, MS
Published 2024-04-01

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.

by Carolyn Tieu, Eleanor J Lucas, Mindi DePaola, Lori Rosman, G Caleb Alexander
Published 2018-01-01

Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study

by Hsien-Yen Chang, Hadi Kharrazi, Dave Bodycombe, Jonathan P. Weiner, G. Caleb Alexander
Published 2018-05-01

The availability of pharmacies in the United States: 2007-2015.

by Dima Mazen Qato, Shannon Zenk, Jocelyn Wilder, Rachel Harrington, Darrell Gaskin, G Caleb Alexander
Published 2017-01-01

Tobacco control policies and smoking cessation treatment utilization: A moderated mediation analysis.

by Johannes Thrul, Kira E Riehm, Joanna E Cohen, G Caleb Alexander, Jon S Vernick, Ramin Mojtabai
Published 2021-01-01

Protocol: mixed-methods study to evaluate implementation, enforcement, and outcomes of U.S. state laws intended to curb high-risk opioid prescribing

by Emma E. McGinty, Elizabeth A. Stuart, G. Caleb Alexander, Colleen L. Barry, Mark C. Bicket, Lainie Rutkow
Published 2018-02-01

National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

by Rishav Adhikari, Kunal Jha, Zeina Dardari, James Heyward, Roger S. Blumenthal, Robert H. Eckel, G. Caleb Alexander, Michael J. Blaha
Published 2022-05-01

Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.

by Sheriza N Baksh, Jodi B Segal, Mara McAdams-DeMarco, Rita R Kalyani, G Caleb Alexander, Stephan Ehrhardt
Published 2020-01-01